{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:21:20Z","timestamp":1793996480600,"version":"4.8.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T00:00:00Z","timestamp":1664841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T00:00:00Z","timestamp":1664841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100019540","name":"Natural Science Fund for Distinguished Young Scholars of Zhejiang Province","doi-asserted-by":"crossref","award":["LR22H260001"],"award-info":[{"award-number":["LR22H260001"]}],"id":[{"id":"10.13039\/501100019540","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970494"],"award-info":[{"award-number":["81970494"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016104","name":"Key Project of Research and Development Plan of Hunan Province","doi-asserted-by":"crossref","award":["2019SK2041"],"award-info":[{"award-number":["2019SK2041"]}],"id":[{"id":"10.13039\/100016104","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Metabolic dysfunction-associated fatty liver disease (MAFLD) is recently recognized as a condition featured with metabolic dysfunctions in liver. It has been supposed that MAFLD might contribute to the development of IBD, but evidence from prospective cohort studies is lacking and inconclusive.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 221,546 females and 183,867 males from the UK Biobank cohort enrolled in 2006\u20132010 were included to examine whether MAFLD and liver function markers were related to incident IBD. MAFLD was identified based on hepatic steatosis defined by fatty liver index plus the prevalence of overweight, type 2 diabetes mellitus, or at least two metabolic abnormalities. Biomarker related to liver function (albumin [ALB], alkaline phosphatase [ALP], alanine transaminase [ALT], aspartate transaminase [AST]; gamma-glutamyl transferase [GGT], total bilirubin [TB], total protein [TP]) was measured using colorimetric or enzymatic assays. The incidence of IBD was ascertained based on primary care and inpatient records. Cox proportional hazard model was used to estimate hazard ratios (HRs) with 95% confidence intervals (CI) for the magnitude of their associations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>With a mean follow-up of 12.1\u00a0years, 2228 incident IBD cases were documented. We identified 150,385 individuals with MAFLD at baseline and 86% participants\u2019 circulating liver function markers were within the normal range. Participants with MAFLD were associated with a 12% (HR 1.12, 95% CI 1.03, 1.23, <jats:italic>p<\/jats:italic>\u2009=\u20090.012) increased risk of IBD compared with those without MAFLD at baseline; the association was stronger (<jats:italic>p<\/jats:italic>-<jats:sub>Heterogeneity<\/jats:sub>\u2009=\u20090.006) with Crohn's disease (HR 1.35, 95% CI 1.15, 1.59, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) than ulcerative colitis (HR 1.03, 95% CI 0.93, 1.15, <jats:italic>p<\/jats:italic>\u2009=\u20090.57). As for the serum liver function markers, the HRs of IBD for per 1-SD increment in ALB, ALP, AST, and TB concentration were 0.86 (95% CI 0.83, 0.90, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), 1.18 (95% CI 1.13, 1.24, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), 0.95 (95% CI 0.91, 0.99, <jats:italic>p<\/jats:italic>\u2009=\u20090.027), 0.92 (95% CI 0.87, 0.96, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), respectively. We did not observe significant associations of GGT and TP with IBD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Individuals with MAFLD were at increased risk of developing IBD, especially CD, but not UC. Circulating levels of liver function biomarkers as the surrogate indicators of MAFLD were also associated with IBD risk.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12072-022-10424-6","type":"journal-article","created":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T11:04:21Z","timestamp":1664881461000},"page":"202-214","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Metabolic dysfunction-associated fatty liver disease and liver function markers are associated with Crohn\u2019s disease but not Ulcerative Colitis: a prospective cohort study"],"prefix":"10.1007","volume":"17","author":[{"given":"Jie","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lintao","family":"Dan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinru","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minzi","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese","family":"Hesketh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7281-1078","authenticated-orcid":false,"given":"Xiaoyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,4]]},"reference":[{"key":"10424_CR1","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/nrgastro.2015.150","volume":"12","author":"GG Kaplan","year":"2015","unstructured":"Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12:720\u2013727","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10424_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22179139","author":"CK Hyun","year":"2021","unstructured":"Hyun CK. Molecular and pathophysiological links between metabolic disorders and inflammatory bowel diseases. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22179139","journal-title":"Int J Mol Sci"},{"key":"10424_CR3","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1097\/MIB.0000000000000283","volume":"21","author":"H Khalili","year":"2015","unstructured":"Khalili H, Ananthakrishnan AN, Konijeti GG, Higuchi LM, Fuchs CS, Richter JM, et al. Measures of obesity and risk of Crohn\u2019s disease and ulcerative colitis. Inflamm Bowel Dis. 2015;21:361\u2013368","journal-title":"Inflamm Bowel Dis"},{"key":"10424_CR4","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.dld.2018.01.121","volume":"50","author":"M Voutilainen","year":"2018","unstructured":"Voutilainen M, Hutri-K\u00e4h\u00f6nen N, Tossavainen P, Sipponen T, Pitk\u00e4nen N, Laitinen T, et al. Low childhood high density lipoprotein cholesterol levels and subsequent risk for chronic inflammatory bowel disease. Dig Liver Dis. 2018;50:348\u2013352","journal-title":"Dig Liver Dis"},{"key":"10424_CR5","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","volume":"158","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999-2014.e1","journal-title":"Gastroenterology"},{"key":"10424_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.01.039","author":"JC Rodriguez-Duque","year":"2022","unstructured":"Rodriguez-Duque JC, Calleja JL, Iruzubieta P, Hern\u00e1ndez-Conde M, Rivas-Rivas C, Vera MI, et al. Increased risk of MAFLD and liver fibrosis in inflammatory bowel disease independent of classic metabolic risk factors. Clin Gastroenterol Hepatol. 2022. https:\/\/doi.org\/10.1016\/j.cgh.2022.01.039","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10424_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001779","volume":"12","author":"C Sudlow","year":"2015","unstructured":"Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12: e1001779","journal-title":"PLoS Med"},{"key":"10424_CR8","unstructured":"UK Biobank. Data providers and dates of data availability. available at: https:\/\/biobank.ndph.ox.ac.uk\/ukb\/exinfo.cgi?src=Data_providers_and_dates. Accessed 3 Mar 2022"},{"key":"10424_CR9","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1136\/adc.88.11.995","volume":"88","author":"A Sawczenko","year":"2003","unstructured":"Sawczenko A, Sandhu BK. Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch Dis Child. 2003;88:995\u20131000","journal-title":"Arch Dis Child"},{"key":"10424_CR10","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/00401706.1983.10487848","volume":"25","author":"B Rosner","year":"1983","unstructured":"Rosner B. Percentage points for a generalized ESD Many-Outlier procedure. Technometrics. 1983;25:165\u2013172","journal-title":"Technometrics"},{"key":"10424_CR11","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202\u2013209","journal-title":"J Hepatol"},{"key":"10424_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-230X-6-33","volume":"6","author":"G Bedogni","year":"2006","unstructured":"Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33","journal-title":"BMC Gastroenterol"},{"key":"10424_CR13","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","volume":"156","author":"L Castera","year":"2019","unstructured":"Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156:1264\u201381.e4","journal-title":"Gastroenterology"},{"key":"10424_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2021.154955","volume":"127","author":"Z Liu","year":"2022","unstructured":"Liu Z, Lin C, Suo C, Zhao R, Jin L, Zhang T, et al. Metabolic dysfunction\u2013associated fatty liver disease and the risk of 24 specific cancers. Metabolism. 2022;127: 154955","journal-title":"Metabolism"},{"key":"10424_CR15","doi-asserted-by":"publisher","first-page":"e855","DOI":"10.1016\/j.cgh.2020.12.033","volume":"20","author":"Z Liu","year":"2022","unstructured":"Liu Z, Suo C, Shi O, Lin C, Zhao R, Yuan H, et al. The health impact of MAFLD, a novel disease cluster of NAFLD, is amplified by the integrated effect of fatty liver disease-related genetic variants. Clin Gastroenterol Hepatol. 2022;20:e855\u2013e875","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10424_CR16","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1530\/EJE-14-0112","volume":"171","author":"DJ Cuthbertson","year":"2014","unstructured":"Cuthbertson DJ, Weickert MO, Lythgoe D, Sprung VS, Dobson R, Shoajee-Moradie F, et al. External validation of the fatty liver index and lipid accumulation product indices, using 1H-magnetic resonance spectroscopy, to identify hepatic steatosis in healthy controls and obese, insulin-resistant individuals. Eur J Endocrinol. 2014;171:561\u2013569","journal-title":"Eur J Endocrinol"},{"key":"10424_CR17","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/liv.15139","volume":"42","author":"I Ayada","year":"2022","unstructured":"Ayada I, van Kleef LA, Alferink LJM, Li P, de Knegt RJ, Pan Q. Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: focusing on the non-overlap groups. Liver Int. 2022;42:277\u2013287","journal-title":"Liver Int"},{"key":"10424_CR18","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/S0016-5085(00)70364-7","volume":"118","author":"V Ratziu","year":"2000","unstructured":"Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, et al. Liver fibrosis in overweight patients. Gastroenterology. 2000;118:1117\u20131123","journal-title":"Gastroenterology"},{"key":"10424_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.517","author":"PY Kwo","year":"2017","unstructured":"Kwo PY, Cohen SM, Lim JK. ACG clinical guideline: evaluation of abnormal liver chemistries. Offi J Am Coll Gastroenterol ACG. 2017. https:\/\/doi.org\/10.1038\/ajg.2016.517","journal-title":"Offi J Am Coll Gastroenterol ACG"},{"key":"10424_CR20","unstructured":"UK Biobank. UK Biobank Biomarker Project. 2019. available at: https:\/\/biobank.ndph.ox.ac.uk\/ukb\/ukb\/docs\/serum_biochemistry.pdf. Accessed 3 Mar 2022"},{"key":"10424_CR21","first-page":"665","volume":"22","author":"S Kim","year":"2015","unstructured":"Kim S. ppcor: An R package for a fast calculation to semi-partial correlation coefficients. Commun Stat Appl Methods. 2015;22:665\u2013674","journal-title":"Commun Stat Appl Methods"},{"key":"10424_CR22","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1053\/j.gastro.2017.10.034","volume":"154","author":"\u00c5H Everhov","year":"2018","unstructured":"Everhov \u00c5H, Halfvarson J, Myrelid P, Sachs MC, Nordenvall C, S\u00f6derling J, et al. Incidence and treatment of patients diagnosed with inflammatory bowel diseases at 60 years or older in sweden. Gastroenterology. 2018;154:518\u201328.e15","journal-title":"Gastroenterology"},{"key":"10424_CR23","doi-asserted-by":"publisher","first-page":"344","DOI":"10.2307\/590279","volume":"40","author":"D Blane","year":"1987","unstructured":"Blane D, Townsend P, Phillimore P, Beattie A. Health and deprivation: inequality and the North. Br J Sociol. 1987;40:344","journal-title":"Br J Sociol"},{"key":"10424_CR24","unstructured":"US Department of Agriculture, US department of health and human services. Dietary guidelines for americans 2020\u20132025. available at: https:\/\/www.dietaryguidelines.gov\/resources\/2020-2025-dietary-guidelines-online-materials. Accessed 23 Mar 2022"},{"key":"10424_CR25","doi-asserted-by":"publisher","DOI":"10.1017\/jns.2017.66","volume":"7","author":"KE Bradbury","year":"2018","unstructured":"Bradbury KE, Young HJ, Guo W, Key TJ. Dietary assessment in UK Biobank: an evaluation of the performance of the touchscreen dietary questionnaire. J Nutr Sci. 2018;7: e6","journal-title":"J Nutr Sci"},{"key":"10424_CR26","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1001\/jama.2019.9879","volume":"322","author":"I Lourida","year":"2019","unstructured":"Lourida I, Hannon E, Littlejohns TJ, Langa KM, Hypp\u00f6nen E, Kuzma E, et al. Association of lifestyle and genetic risk with incidence of dementia. JAMA. 2019;322:430\u2013437","journal-title":"JAMA"},{"key":"10424_CR27","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1161\/CIRCULATIONAHA.109.192703","volume":"121","author":"DM Lloyd-Jones","year":"2010","unstructured":"Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: the american heart association\u2019s strategic impact goal through 2020 and beyond. Circulation. 2010;121:586\u2013613","journal-title":"Circulation"},{"key":"10424_CR28","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1111\/jgs.17089","volume":"69","author":"JKL Mak","year":"2021","unstructured":"Mak JKL, Kuja-Halkola R, Wang Y, H\u00e4gg S, Jylh\u00e4v\u00e4 J. Frailty and comorbidity in predicting community COVID-19 mortality in the U.K Biobank: the effect of sampling. J Am Geriatr Soc. 2021;69:1128\u20131139","journal-title":"J Am Geriatr Soc"},{"key":"10424_CR29","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1093\/oxfordjournals.aje.a009034","volume":"145","author":"EL Korn","year":"1997","unstructured":"Korn EL, Graubard BI, Midthune D. Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol. 1997;145:72\u201380","journal-title":"Am J Epidemiol"},{"key":"10424_CR30","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","volume":"81","author":"PM Grambsch","year":"1994","unstructured":"Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515\u2013526","journal-title":"Biometrika"},{"key":"10424_CR31","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/sim.6793","volume":"35","author":"M Wang","year":"2016","unstructured":"Wang M, Spiegelman D, Kuchiba A, Lochhead P, Kim S, Chan AT, et al. Statistical methods for studying disease subtype heterogeneity. Stat Med. 2016;35:782\u2013800","journal-title":"Stat Med"},{"key":"10424_CR32","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1093\/oxfordjournals.aje.a010013","volume":"150","author":"R Clarke","year":"1999","unstructured":"Clarke R, Shipley M, Lewington S, Youngman L, Collins R, Marmot M, et al. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol. 1999;150:341\u2013353","journal-title":"Am J Epidemiol"},{"key":"10424_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-19425-7","volume-title":"Regression modeling strategies: with applications to linear models logistic and ordinal regression, and survival analysis","author":"FE Harrell","year":"2015","unstructured":"Harrell FE. Regression modeling strategies: with applications to linear models logistic and ordinal regression, and survival analysis. Cham: Springer; 2015"},{"key":"10424_CR34","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1002\/hep.31726","volume":"74","author":"H Hagstr\u00f6m","year":"2021","unstructured":"Hagstr\u00f6m H, Adams LA, Allen AM, Byrne CD, Chang Y, Gr\u00f8nbaek H, et al. Administrative coding in electronic health care record-based research of NAFLD: an expert panel consensus statement. Hepatology. 2021;74:474\u2013482","journal-title":"Hepatology"},{"key":"10424_CR35","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.0.CO;2-R","volume":"18","author":"S Van Buuren","year":"1999","unstructured":"Van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med. 1999;18:681\u2013694","journal-title":"Stat Med"},{"key":"10424_CR36","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/j.cgh.2020.12.022","volume":"19","author":"H Lee","year":"2021","unstructured":"Lee H, Lee YH, Kim SU, Kim HC. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study. Clin Gastroenterol Hepatol. 2021;19:2138\u201347.e10","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10424_CR37","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3727\/105221618X15156018385515","volume":"18","author":"JYL Chiang","year":"2018","unstructured":"Chiang JYL, Ferrell JM. Bile acid metabolism in liver pathobiology. Gene Expr. 2018;18:71\u201387","journal-title":"Gene Expr"},{"key":"10424_CR38","first-page":"261","volume":"5","author":"MC Cheah","year":"2017","unstructured":"Cheah MC, McCullough AJ, Goh GB. Current modalities of fibrosis assessment in non-alcoholic fatty liver disease. J Clin Transl Hepatol. 2017;5:261\u2013271","journal-title":"J Clin Transl Hepatol"},{"key":"10424_CR39","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/ije\/dyt192","volume":"43","author":"SK Kunutsor","year":"2014","unstructured":"Kunutsor SK, Apekey TA, Seddoh D, Walley J. Liver enzymes and risk of all-cause mortality in general populations: a systematic review and meta-analysis. Int J Epidemiol. 2014;43:187\u2013201","journal-title":"Int J Epidemiol"},{"key":"10424_CR40","doi-asserted-by":"publisher","first-page":"e561","DOI":"10.1097\/RHU.0000000000001596","volume":"27","author":"S Sangha","year":"2021","unstructured":"Sangha S, Lenert A, Dawoud S, Kaur A, Yazan H, Voigt MD, et al. Atypical large vessel vasculitis presenting with cholestatic liver abnormalities: case-based review. J Clin Rheumatol. 2021;27:e561\u2013e567","journal-title":"J Clin Rheumatol"},{"key":"10424_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2019-000368","volume":"7","author":"IV Maev","year":"2020","unstructured":"Maev IV, Samsonov AA, Palgova LK, Pavlov CS, Shirokova EN, Vovk EI, et al. Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: real-life observational study from Russia. BMJ Open Gastroenterol. 2020;7: e000368","journal-title":"BMJ Open Gastroenterol"},{"key":"10424_CR42","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1002\/ijc.33351","volume":"148","author":"MM He","year":"2021","unstructured":"He MM, Fang Z, Hang D, Wang F, Polychronidis G, Wang L, et al. Circulating liver function markers and colorectal cancer risk: a prospective cohort study in the UK Biobank. Int J Cancer. 2021;148:1867\u20131878","journal-title":"Int J Cancer"},{"key":"10424_CR43","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/S0016-5085(99)70042-9","volume":"116","author":"AF Hofmann","year":"1999","unstructured":"Hofmann AF. Bile acids, cholesterol, gallstone calcification, and the enterohepatic circulation of bilirubin. Gastroenterology. 1999;116:1276\u20131277","journal-title":"Gastroenterology"},{"key":"10424_CR44","doi-asserted-by":"publisher","first-page":"18321","DOI":"10.1073\/pnas.1406199111","volume":"111","author":"CM Dejea","year":"2014","unstructured":"Dejea CM, Wick EC, Hechenbleikner EM, White JR, Mark Welch JL, Rossetti BJ, et al. Microbiota organization is a distinct feature of proximal colorectal cancers. Proc Natl Acad Sci USA. 2014;111:18321\u201318326","journal-title":"Proc Natl Acad Sci USA"},{"key":"10424_CR45","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1089\/thy.2015.0061","volume":"25","author":"E Sisti","year":"2015","unstructured":"Sisti E, Coco B, Menconi F, Leo M, Rocchi R, Latrofa F, et al. Age and dose are major risk factors for liver damage associated with intravenous glucocorticoid pulse therapy for graves\u2019 orbitopathy. Thyroid. 2015;25:846\u2013850","journal-title":"Thyroid"},{"key":"10424_CR46","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001206","author":"MH Derakhshan","year":"2020","unstructured":"Derakhshan MH, Dean L, Jones GT, Siebert S, Gaffney K. Predictors of extra-articular manifestations in axial spondyloarthritis and their influence on TNF-inhibitor prescribing patterns: results from the british society for rheumatology biologics register in ankylosing spondylitis. RMD Open. 2020. https:\/\/doi.org\/10.1136\/rmdopen-2020-001206","journal-title":"RMD Open"},{"key":"10424_CR47","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1111\/apt.12963","volume":"40","author":"L Fedchuk","year":"2014","unstructured":"Fedchuk L, Nascimbeni F, Pais R, Charlotte F, Housset C, Ratziu V. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2014;40:1209\u20131222","journal-title":"Aliment Pharmacol Ther"},{"key":"10424_CR48","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12916-019-1251-7","volume":"17","author":"S Khalatbari-Soltani","year":"2019","unstructured":"Khalatbari-Soltani S, Imamura F, Brage S, De Lucia RE, Griffin SJ, Wareham NJ, et al. The association between adherence to the Mediterranean diet and hepatic steatosis: cross-sectional analysis of two independent studies, the UK Fenland study and the Swiss CoLaus study. BMC Med. 2019;17:19","journal-title":"BMC Med"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-022-10424-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-022-10424-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-022-10424-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T19:24:21Z","timestamp":1675625061000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-022-10424-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,4]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10424"],"URL":"https:\/\/doi.org\/10.1007\/s12072-022-10424-6","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,4]]},"assertion":[{"value":"22 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jie Chen, Lintao Dan, Xinru Tu, Yuhao Sun, Minzi Deng, Xuejie Chen, Therese Hesketh, Ran Li, Xiaoyan Wang, and Xue Li declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The ethical approval was granted for the UK Biobank by the North West-Haydock Research Ethics Committee (REC reference: 16\/NW\/0274). All participants provided informed consent through electronic signature at baseline assessment. This study was conducted with the UK Biobank Resource under application number 73595.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}